[{"id":"46e4deaa-8f21-4cac-8410-39826ed5483d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006695","created_at":"2021-01-17T23:54:05.754Z","updated_at":"2024-07-02T16:35:38.269Z","phase":"Phase 2","brief_title":"Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00006695","lead_sponsor":"University of Nebraska","biomarkers":" CD20 • CD34","pipe":"","alterations":" ","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2000","start_date":" 04/01/2000","primary_txt":" Primary completion: 09/01/2005","primary_completion_date":" 09/01/2005","study_txt":" Completion: 12/16/2014","study_completion_date":" 12/16/2014","last_update_posted":"2023-09-01"},{"id":"0455d3b2-6dcd-49fb-b18e-54e9cb028f9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01484093","created_at":"2021-01-18T06:12:10.347Z","updated_at":"2025-02-25T13:17:20.473Z","phase":"Phase 1/2","brief_title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","source_id_and_acronym":"NCT01484093","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CCND1","pipe":"","alterations":" ","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 11/29/2011","start_date":" 11/29/2011","primary_txt":" Primary completion: 08/11/2023","primary_completion_date":" 08/11/2023","study_txt":" Completion: 08/11/2023","study_completion_date":" 08/11/2023","last_update_posted":"2023-08-16"},{"id":"0f196312-39a4-4784-97b3-69fcc7a694c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00329030","created_at":"2021-01-18T01:08:08.536Z","updated_at":"2024-07-02T16:36:21.719Z","phase":"Phase 3","brief_title":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","source_id_and_acronym":"NCT00329030","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD20 • CD8 • IL2RA • PTPRC • NCAM1 • ISG20","pipe":"","alterations":" ","tags":["CD20 • CD8 • IL2RA • PTPRC • NCAM1 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 224","initiation":"Initiation: 12/01/2005","start_date":" 12/01/2005","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2021-11-01"},{"id":"da857301-e610-40f7-80ae-f6f2788ca11c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00484874","created_at":"2021-01-18T01:44:00.666Z","updated_at":"2025-02-25T13:09:22.124Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma","source_id_and_acronym":"NCT00484874","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 06/01/2007","start_date":" 06/01/2007","primary_txt":" Primary completion: 01/01/2014","primary_completion_date":" 01/01/2014","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2018-08-01"},{"id":"23ef9e45-b336-40c9-a79f-a891d09a44a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01536561","created_at":"2021-01-18T06:29:22.052Z","updated_at":"2024-07-02T16:37:18.258Z","phase":"Phase 1","brief_title":"Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT01536561","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 04/24/1990","start_date":" 04/24/1990","primary_txt":" Primary completion: 07/02/1997","primary_completion_date":" 07/02/1997","study_txt":" Completion: 10/16/2009","study_completion_date":" 10/16/2009","last_update_posted":"2017-08-31"},{"id":"7e363bf7-3e4a-4c5e-ba3e-5cb2b7650faf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073918","created_at":"2021-01-18T00:11:39.645Z","updated_at":"2024-07-02T16:37:18.718Z","phase":"Phase 2","brief_title":"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00073918","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • Bexxar (iodine I 131 tositumomab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 02/01/1999","start_date":" 02/01/1999","primary_txt":" Primary completion: 10/02/2011","primary_completion_date":" 10/02/2011","study_txt":" Completion: 10/02/2011","study_completion_date":" 10/02/2011","last_update_posted":"2017-08-18"},{"id":"3cda433b-4feb-45de-b358-938e5999e0bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT00992758","created_at":"2021-01-18T03:52:41.543Z","updated_at":"2024-07-02T16:37:19.598Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement","source_id_and_acronym":"NCT00992758","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 05/28/1999","start_date":" 05/28/1999","primary_txt":" Primary completion: 06/07/2012","primary_completion_date":" 06/07/2012","study_txt":" Completion: 06/07/2012","study_completion_date":" 06/07/2012","last_update_posted":"2017-07-25"},{"id":"50ccfbde-5b0b-418a-b9fb-36a93a3b4ebe","acronym":"","url":"https://clinicaltrials.gov/study/NCT00490009","created_at":"2021-01-18T01:45:04.813Z","updated_at":"2025-02-25T13:09:24.479Z","phase":"Phase 2","brief_title":"Phase 2 Study of Bexxar in Relapsed/Refractory DLCL","source_id_and_acronym":"NCT00490009","lead_sponsor":"Susan Knox","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2017-03-30"},{"id":"51a17312-ff73-463b-8d04-baf228cf8e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00950755","created_at":"2021-01-18T03:41:52.161Z","updated_at":"2024-07-02T16:37:26.491Z","phase":"Phase 2","brief_title":"Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology","source_id_and_acronym":"NCT00950755","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 06/01/1998","start_date":" 06/01/1998","primary_txt":" Primary completion: 04/01/2011","primary_completion_date":" 04/01/2011","study_txt":" Completion: 04/01/2011","study_completion_date":" 04/01/2011","last_update_posted":"2017-01-18"},{"id":"71caefb6-faa7-4321-bc0b-de461c202bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00933335","created_at":"2021-01-18T03:36:52.031Z","updated_at":"2024-07-02T16:37:26.453Z","phase":"Phase 2","brief_title":"Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab","source_id_and_acronym":"NCT00933335","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20 • CSF2","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 08/01/1998","start_date":" 08/01/1998","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 08/01/2010","study_completion_date":" 08/01/2010","last_update_posted":"2017-01-18"},{"id":"fed89cf8-adeb-44ed-b6b2-aa58741654e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01573000","created_at":"2021-01-18T06:40:35.357Z","updated_at":"2024-07-02T16:37:26.460Z","phase":"Phase 2","brief_title":"A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT01573000","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 09/01/1998","start_date":" 09/01/1998","primary_txt":" Primary completion: 04/01/2001","primary_completion_date":" 04/01/2001","study_txt":" Completion: 04/01/2010","study_completion_date":" 04/01/2010","last_update_posted":"2017-01-18"},{"id":"28987d88-439c-4a77-b4af-570f6f1bf39b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01868035","created_at":"2021-01-18T08:21:31.398Z","updated_at":"2024-07-02T16:37:26.709Z","phase":"Phase 2","brief_title":"Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP","source_id_and_acronym":"NCT01868035","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/01/2000","start_date":" 05/01/2000","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2017-01-09"},{"id":"79f861ee-a572-44f3-86fc-5f7a7488263a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00268203","created_at":"2021-01-18T00:54:44.282Z","updated_at":"2024-07-02T16:37:26.698Z","phase":"Phase 2","brief_title":"Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00268203","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 765","initiation":"Initiation: 09/01/1998","start_date":" 09/01/1998","primary_txt":" Primary completion: 03/01/2000","primary_completion_date":" 03/01/2000","study_txt":" Completion: 02/01/2013","study_completion_date":" 02/01/2013","last_update_posted":"2017-01-09"},{"id":"bb43f49e-d4dd-491d-8dd8-7f11c9cf72f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00938041","created_at":"2021-01-18T03:38:18.941Z","updated_at":"2024-07-02T16:37:26.713Z","phase":"Phase 2","brief_title":"Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody","source_id_and_acronym":"NCT00938041","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 04/01/1998","start_date":" 04/01/1998","primary_txt":" Primary completion: 05/01/2003","primary_completion_date":" 05/01/2003","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2017-01-09"},{"id":"f9baf346-ffe1-4347-9712-b2f0930775bf","acronym":"RIT-II-001","url":"https://clinicaltrials.gov/study/NCT01224821","created_at":"2021-01-18T04:55:16.742Z","updated_at":"2024-07-02T16:37:27.141Z","phase":"Phase 2","brief_title":"Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies","source_id_and_acronym":"NCT01224821 - RIT-II-001","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 12/01/1995","start_date":" 12/01/1995","primary_txt":" Primary completion: 11/01/1997","primary_completion_date":" 11/01/1997","study_txt":" Completion: 05/01/2008","study_completion_date":" 05/01/2008","last_update_posted":"2016-12-12"},{"id":"785a18d2-544c-43a7-b017-a54743392b32","acronym":"","url":"https://clinicaltrials.gov/study/NCT00996593","created_at":"2021-01-18T03:53:42.053Z","updated_at":"2024-07-02T16:37:27.484Z","phase":"Phase 2","brief_title":"Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab","source_id_and_acronym":"NCT00996593","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/01/1998","start_date":" 07/01/1998","primary_txt":" Primary completion: 04/01/2001","primary_completion_date":" 04/01/2001","study_txt":" Completion: 08/01/2009","study_completion_date":" 08/01/2009","last_update_posted":"2016-11-23"},{"id":"8573d633-658c-48b8-b0c7-06f3ad83350e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00434629","created_at":"2021-01-18T01:32:02.944Z","updated_at":"2025-02-25T13:09:03.687Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant","source_id_and_acronym":"NCT00434629","lead_sponsor":"University of Pennsylvania","biomarkers":" CD20 • CD34","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bexxar (iodine I 131 tositumomab)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/01/2007","start_date":" 02/01/2007","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2016-08-17"}]